Summary of LanzaTech Global Inc. Q3 2024 Earnings Call

1Key Financial Results and Metrics:

Total Revenue: $9.9 million, significantly below the target by approximately $7 million.

Biorefining Revenues: $5.9 million, similar to Q2 but down $6.5 million year-over-year.

Joint Development Agreements and Contract Research: $1.8 million, down from $2.8 million in Q2.

CarbonSmart Product Sales: $2.2 million, up from $0.9 million in Q2.

Gross Margin: 18% of revenue, impacted by lower-margin sales and absence of high-margin LanzaJet share revenue.

Operating Expenses: $34.8 million, up $5 million year-over-year but flat compared to Q2.

Adjusted EBITDA Loss: $27.1 million, compared to a loss of $19.1 million in Q3 2023.

Cash Position: $89.1 million at the end of September, up from $75.8 million in Q2, bolstered by a $40 million investment from Carbon Direct Capital.

2Strategic Updates and Business Highlights:

Business Model Evolution: Transitioning from a licensing-focused model to developing and financing own projects to capture more value and control over timelines.

Project Developments:

Project Drake: A significant ethanol-to-sustainable aviation fuel (SAF) project nearing final investment decision (FID) with a $5 million exclusivity fee received.

Norwegian Project: Expected to reach FID soon, potentially generating $20 million in revenue.

Joint Venture with Olayan Group: Focused on expanding commercial opportunities in the Middle East.

New Product Launch: Introduction of LanzaTech Nutritional Protein, targeting the alternative protein market.

Ethanol Off-take Agreement with ArcelorMittal: Two-stage agreement projected to generate $6 million to $20 million annually.

3Forward Guidance and Outlook:

Q4 2024 Expectations: Anticipated revenue drivers include:

Base business generating approximately $10 million.

Potential $20 million from the Norwegian project upon positive FID.

Additional revenue from Project Drake and Project SECURE.

Possible revenue from LanzaJet sublicensing agreements.

Long-term Growth: Confidence in 2025 and beyond, driven by evolving business model and project pipeline.

4Bad News, Challenges, or Points of Concern:

Revenue Shortfall: Q3 revenue significantly below expectations due to delays in LanzaJet sublicensing agreements and depressed ethanol pricing.

Increased Operating Costs: While expenses are controlled, project development costs are high, impacting profitability.

Market Dynamics: Challenges in ethanol pricing affecting CarbonSmart sales and overall revenue generation.

Timing Uncertainty: Multiple projects have uncertain timelines, leading to potential volatility in revenue recognition.

5Notable Q&A Insights:

Project Drake Revenue: The $5 million received is expected to be recognized as revenue in Q4, separate from the base business revenue.

Cost Control Initiatives: Despite rising operating costs, management is focused on reducing specific expenses while incurring costs for project development.

Infrastructure Partnerships: LanzaTech is exploring multiple partnerships beyond Brookfield to finance projects, enhancing flexibility and capital access.

Nutritional Protein Production: The product is 85% protein with all essential amino acids, and while nitrogen must be added, the carbon intensity is significantly lower compared to traditional animal protein sources.

Market Interest: Strong interest from emitters and infrastructure partners in low-carbon projects, indicating a favorable environment for future growth. Overall, LanzaTech is navigating challenges in revenue generation and cost management while strategically positioning itself for future growth through project development and new product offerings.